ADVERTISEMENT

Breast cancer: no need for sequential endocrine therapy past 5 years

Miriam Davis   |   Clinical Summary   |   28 March 2023
ADVERTISEMENT

Takeaway

  • 6 years of aromatase inhibitor therapy is no more effective than 3 years in postmenopausal women who had previously received 2-3 years of tamoxifen for hormone receptor-positive breast cancer, suggests the 10-year results of the DATA trial of sequential endocrine therapy.
  • Findings by Dutch investigators appear in The Lancet...

          

Topic Challenges

left
right